| Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). | |
| | |
MedLine Citation:
|
PMID: 23144449 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
INTRODUCTION: Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and is a marker and predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml to reduce SLE flares. PATIENTS AND METHODS: [HCQ] was measured in 573 patients with SLE (stable disease and SELENA-SLEDAI≤12) treated with HCQ for at least 6 months. Patients with [HCQ] from 100 to 750 ng/ml were randomised to one of two treatment groups: no daily dose change (group 1) or increased HCQ dose to achieve the target [HCQ] (group 2). The primary end point was the number of patients with flares during 7 months of follow-up. RESULTS: Overall, mean [HCQ] was 918±451 ng/ml. Active SLE was less prevalent in patients with higher [HCQ]. A total of 171 patients were randomised and followed for 7 months. SLE flare rates were similar in the two groups (25% in group 1 vs 27.6% in group 2; p=0.7), but a significant spontaneous increase in [HCQ] in both groups between inclusion and randomisation strongly suggested improved treatment adherence. Patients at the therapeutic target throughout follow-up tended to have fewer flares than those with low [HCQ] (20.5% vs 35.1%, p=0.12). CONCLUSIONS: Although low [HCQ] is associated with higher SLE activity, adapting the HCQ dose did not reduce SLE flares over a 7-month follow-up. CLINICALTRIALS.GOV: NCT00413361. |
| | |
Authors:
|
Nathalie Costedoat-Chalumeau; Lionel Galicier; Olivier Aumaître; Camille Francès; Véronique Le Guern; Frédéric Lioté; Amar Smail; Nicolas Limal; Laurent Perard; Hélène Desmurs-Clavel; Du Le Thi Huong Boutin; Bouchra Asli; Jean-Emmanuel Kahn; Jacques Pourrat; Laurent Sailler; Félix Ackermann; Thomas Papo; Karim Sacré; Olivier Fain; Jerome Stirnemann; Patrice Cacoub; Moez Jallouli; Gaelle Leroux; Judith Cohen-Bittan; Marie-Laure Tanguy; Jean-Sébastien Hulot; Philippe Lechat; Lucile Musset; Zahir Amoura; Jean-Charles Piette; |
Related Documents
:
|
9184979 - Importance of mastoid pneumatization on secretory otitis media. 22473139 - The efficacy of schroth`s 3-dimensional exercise therapy in the treatment of adolescent... 19128609 - Effectiveness of royal jelly on tympanic membrane perforations: an experimental study. 12172269 - Risk-benefit analysis of using the middle fossa approach for acoustic neuromas with >10... 23348489 - Advanced therapeutic methods for the treatment of meningococcal septic shock - case rep... 23114869 - Arthroscopic treatment for acute septic arthritis of the hip joint in adults. 23557789 - Bone mineral density 5 years after parathyroidectomy in hemodialysis patients with seco... 12026199 - Treatment of developmental dysplasia of the hip before walking: results of closed reduc... 19643289 - Long-term follow-up of basal joint resection arthroplasty of the thumb with transfer of... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-10 |
Journal Detail:
|
Title: Annals of the rheumatic diseases Volume: - ISSN: 1468-2060 ISO Abbreviation: Ann. Rheum. Dis. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372355 Medline TA: Ann Rheum Dis Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1UPMC, Université Paris 6, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic disea...
Next Document: Long-term safety of pegloticase in chronic gout refractory to conventional treatment.